[go: up one dir, main page]

MX2015007446A - Anticuerpos terapeuticos para cd47. - Google Patents

Anticuerpos terapeuticos para cd47.

Info

Publication number
MX2015007446A
MX2015007446A MX2015007446A MX2015007446A MX2015007446A MX 2015007446 A MX2015007446 A MX 2015007446A MX 2015007446 A MX2015007446 A MX 2015007446A MX 2015007446 A MX2015007446 A MX 2015007446A MX 2015007446 A MX2015007446 A MX 2015007446A
Authority
MX
Mexico
Prior art keywords
iri
monoclonal antibodies
binding fragments
antigen
ischemia
Prior art date
Application number
MX2015007446A
Other languages
English (en)
Inventor
William A Frazier
Pamela T Manning
Gerhard Frey
Hwai Wen Chang
Original Assignee
Vasculox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasculox Inc filed Critical Vasculox Inc
Publication of MX2015007446A publication Critical patent/MX2015007446A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan anticuerpos monoclonales, y fragmentos de unión a antígenos de los mismos, que se unen e inhiben la actividad de CD47, así como anticuerpos monoclonales, y fragmentos de unión a antígenos de los mismos, que compiten con los primeros por la unión a CD47. También se proporcionan combinaciones de cualquiera de los precedentes. Tales compuestos de anticuerpos son efectivos en modos diversos en 1) el tratamiento de isquemia tisular y lesión por isquemia-reperfusión (IRI) en el entorno de conservación y trasplante de órganos, hipertensión pulmonar, anemia de células falciformes, infarto del miocardio, apoplejía y otros casos de cirugía y/o trauma en los cuales la IRI es un componente de la patogénesis, 2) en el tratamiento de enfermedades autoinmunes e inflamatorias y 3) como agentes anticancerosos que son tóxicos para células cancerosas susceptibles, que promueven (incrementan) su captación y depuración fagocítica y/o que eliminan directamente tales células.
MX2015007446A 2012-12-12 2013-12-12 Anticuerpos terapeuticos para cd47. MX2015007446A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736301P 2012-12-12 2012-12-12
US201361833691P 2013-06-11 2013-06-11
PCT/US2013/074766 WO2014093678A2 (en) 2012-12-12 2013-12-12 Therapeutic cd47 antibodies

Publications (1)

Publication Number Publication Date
MX2015007446A true MX2015007446A (es) 2015-12-07

Family

ID=50935081

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007446A MX2015007446A (es) 2012-12-12 2013-12-12 Anticuerpos terapeuticos para cd47.

Country Status (16)

Country Link
US (4) US20140363442A1 (es)
EP (1) EP2931751B1 (es)
JP (1) JP6572131B2 (es)
KR (1) KR20150093770A (es)
CN (1) CN105102479B (es)
AU (1) AU2013359167B2 (es)
BR (1) BR112015013431A2 (es)
CA (1) CA2894439A1 (es)
ES (1) ES2786083T3 (es)
HK (1) HK1216647A1 (es)
IL (1) IL239339A0 (es)
MX (1) MX2015007446A (es)
PH (1) PH12015501318A1 (es)
RU (1) RU2015122228A (es)
SG (1) SG11201504469XA (es)
WO (2) WO2014093678A2 (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
EP2931751B1 (en) 2012-12-12 2020-02-05 Arch Oncology, Inc. Therapeutic cd47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
SMT201900623T1 (it) 2012-12-17 2020-01-14 Trillium Therapeutics Inc Trattamento di cellule di malattia cd47+ con fusioni sirp alpha-fc
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
CA2964173A1 (en) 2014-10-10 2016-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting cd47
AU2015350190B2 (en) 2014-11-18 2021-08-05 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
HUE064960T2 (hu) 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2016141328A2 (en) * 2015-03-04 2016-09-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd47
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
AU2016310348B2 (en) 2015-08-26 2023-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
CA2998548A1 (en) * 2015-09-10 2017-03-16 Affigen, Inc. Sequencing-directed selection of tumor theranostics
EP3349787A4 (en) 2015-09-18 2019-03-27 Arch Oncology, Inc. THERAPEUTIC CD47 ANTIBODIES
EP3353209B1 (en) 2015-09-21 2022-03-16 Erasmus University Medical Center Rotterdam Anti-cd47 antibodies and methods of use
ES2862907T3 (es) 2015-11-27 2021-10-08 Cartherics Pty Ltd Células genéticamente modificadas y usos de las mismas
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
KR102472087B1 (ko) 2016-01-11 2022-11-29 포티 세븐, 인코포레이티드 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
SG11201806110QA (en) * 2016-01-21 2018-08-30 Univ Leland Stanford Junior Treatment of cancer with combinations of immunoregulatory agents
JP2019511552A (ja) * 2016-04-15 2019-04-25 トリリウム セラピューティクス インコーポレイテッド Ｃｄ４７遮断療法におけるマクロファージの刺激
US12344669B2 (en) 2016-06-17 2025-07-01 Changchun Genescience Pharmaceutical Co., Ltd. Anti-CD47 monoclonal antibody and use thereof
CN106084052B (zh) * 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
MX2019004691A (es) 2016-10-20 2019-12-09 I Mab Biopharma Us Ltd Anticuerpos monoclonales cd47 novedosos y sus usos.
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
WO2018081897A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
WO2018095428A1 (zh) * 2016-11-28 2018-05-31 江苏恒瑞医药股份有限公司 Cd47抗体、其抗原结合片段及其医药用途
EP3345924A1 (en) * 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CA3051512A1 (en) * 2017-01-26 2018-08-02 Zlip Holding Limited Cd47 antigen binding unit and uses thereof
SG11201908678XA (en) * 2017-03-27 2019-10-30 Celgene Corp Methods and compositions for reduction of immunogenicity
CA3057718A1 (en) * 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Cd47 blockade therapy
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
CA3072998A1 (en) 2017-08-18 2019-02-21 Ultrahuman Four Limited Binding agents
CN109422811A (zh) * 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
CA3078253A1 (en) 2017-10-18 2019-04-25 Forty Seven, Inc. Anti-cd47 agent-based ovarian cancer therapy
KR20200079511A (ko) 2017-11-01 2020-07-03 허밍버드 바이오사이언스 홀딩스 피티이. 엘티디. Cd47 항원-결합 분자
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
CA3080640C (en) 2017-11-06 2024-04-09 Trillium Therapeutics Inc. Cd47 blockade with radiation therapy
MA51208A (fr) 2017-12-01 2020-10-07 Seattle Genetics Inc Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
WO2019200462A1 (en) * 2018-04-16 2019-10-24 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
CN108484770B (zh) * 2018-05-16 2020-11-13 武汉云克隆科技股份有限公司 重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
CN110538321B (zh) * 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 一种cd47抗体药物组合物及其用途
US11634490B2 (en) 2018-06-15 2023-04-25 Accurus Biosciences, Inc. Blocking antibodies against CD47 and methods of use thereof
CN110615841B (zh) * 2018-06-20 2022-01-04 瑞阳(苏州)生物科技有限公司 抗人cd47单克隆抗体及其应用
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020036977A1 (en) * 2018-08-13 2020-02-20 Arch Oncology, Inc. Therapeutic cd47 antibodies
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
TWI830774B (zh) * 2018-08-31 2024-02-01 大陸商南京聖和藥業股份有限公司 抗cd47抗體及其應用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
WO2020114399A1 (zh) * 2018-12-03 2020-06-11 上海开拓者生物医药有限公司 Cd47抗体及其制备方法和应用
MX2021010531A (es) 2019-03-06 2021-10-01 Jiangsu Hengrui Medicine Co Proteina de fusion bifuncional y uso farmaceutico de la misma.
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
JP7561775B2 (ja) 2019-06-07 2024-10-04 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
WO2020253785A1 (en) * 2019-06-19 2020-12-24 Lepu Biopharma Co., Ltd. Anti-cd47 antibodies and uses thereof
PH12021553197A1 (en) 2019-06-19 2022-11-07 Lepu Biopharma Co Ltd Anti-cd47 antibodies and uses thereof
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
PH12022550223A1 (en) * 2019-07-30 2022-12-19 Akeso Biopharma Inc Anti-human p40 protein domain antibody and use thereof
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CA3148956A1 (en) * 2019-09-03 2021-03-11 Peng Zhang Anti-cd47 monoclonal antibody and use thereof
PL4045083T3 (pl) 2019-10-18 2024-05-13 Forty Seven, Inc. Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
CN114599681B (zh) * 2019-10-25 2024-01-09 上海药明生物技术有限公司 新型抗cd47抗体及其用途
EP4052040A1 (en) 2019-10-31 2022-09-07 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
US20230042316A1 (en) * 2019-11-20 2023-02-09 Abvision, Inc. Monoclonal antibodies that target human cd47 protein
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4077641A1 (en) 2019-12-20 2022-10-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
SI4081305T1 (sl) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Spojine, ki modulirajo diacilglicerol kinazo
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
WO2021190441A1 (zh) * 2020-03-23 2021-09-30 倍而达药业（苏州）有限公司 Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
BR112022019795A2 (pt) * 2020-04-02 2022-11-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Polipeptídeo de ligação a antígeno que se liga a cd47 e uso deste
CN111635459B (zh) * 2020-06-27 2021-01-15 广东赛尔生物科技有限公司 抗cd47抗体及其在治疗癌症中的应用
CA3200514A1 (en) 2020-11-03 2022-05-12 Rdiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
US20230399405A1 (en) * 2020-11-04 2023-12-14 The Trustees Of Dartmouth College Vista agonist for treatment/prevention of ischemic and/or reperfusion injury
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
EP4296282A4 (en) * 2021-02-19 2025-02-26 SHAPERON Inc. SINGLE DOMAIN ANTIBODIES AGAINST CD47 AND USE THEREOF
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
CN112979764B (zh) * 2021-03-26 2022-08-02 复旦大学附属中山医院 特异结合人cd47分子的多肽及其用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024518100A (ja) 2021-05-11 2024-04-24 マイエロイド・セラピューティクス，インコーポレーテッド ゲノム組込みのための方法および組成物
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023159220A1 (en) * 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
IL316058A (en) 2022-04-21 2024-11-01 Gilead Sciences Inc Compounds modulate KRAS G12D
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE143052T1 (de) 1986-07-07 1996-10-15 Centocor Inc Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
CA2303072A1 (en) 1997-09-11 1999-03-18 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
WO2000053634A1 (fr) 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Fv monocatenaire induisant l'apoptose
EA200100264A1 (ru) * 1999-06-21 2001-10-22 Филадельфия Хеалс Энд Эдьюкейшн Корпорейшн Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
CA2468202A1 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
EP1693385A4 (en) 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
GT200500255A (es) 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
JP2007008895A (ja) 2005-07-04 2007-01-18 Chugai Pharmaceut Co Ltd 抗ｃｄ４７抗体とインテグリンリガンドとの併用
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
WO2008043072A2 (en) 2006-10-05 2008-04-10 Biogen Idec Inc. Cd80 antagonists for treating neoplastic disorders
EP2076537B1 (en) * 2006-10-06 2018-08-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prevention of tissue ischemia, related methods and compositions
AU2014201010B2 (en) 2008-01-15 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
CA3221018A1 (en) 2008-01-15 2009-07-23 Ravindra Majeti Markers of acute myeloid leukemia stem cells
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2010017332A2 (en) 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotectants targeting thrombospondin-1 and cd47
ES2927646T3 (es) 2009-09-15 2022-11-08 Univ Leland Stanford Junior Terapia anti-CD47 sinérgica para cánceres hematológicos
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
JP2013518053A (ja) 2010-01-21 2013-05-20 イミュノジェン， インコーポレイテッド 卵巣癌の治療のための組成物および方法
DK2569013T3 (da) * 2010-05-14 2017-02-13 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer til cd47
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US20140271683A1 (en) 2010-12-21 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
PL2812443T3 (pl) * 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
EP2744830A4 (en) 2012-06-21 2015-06-17 Compugen Ltd ANTI-LSR ANTIBODIES AND THEIR USES FOR THE TREATMENT OF CANCER
AU2013353763B2 (en) 2012-12-03 2018-09-13 Novimmune S.A. Anti-CD47 antibodies and methods of use thereof
EP2931751B1 (en) 2012-12-12 2020-02-05 Arch Oncology, Inc. Therapeutic cd47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN114917336A (zh) 2013-03-15 2022-08-19 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
CN103665165B (zh) 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
TW201524998A (zh) 2013-12-31 2015-07-01 Dev Center Biotechnology 抗ｖｅｇｆ抗體及其用途
EP3349787A4 (en) 2015-09-18 2019-03-27 Arch Oncology, Inc. THERAPEUTIC CD47 ANTIBODIES
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
WO2018175790A1 (en) 2017-03-22 2018-09-27 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
US20190309066A1 (en) 2017-03-22 2019-10-10 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers

Also Published As

Publication number Publication date
JP6572131B2 (ja) 2019-09-04
HK1216647A1 (zh) 2016-11-25
AU2013359167B2 (en) 2018-08-23
CA2894439A1 (en) 2014-06-19
KR20150093770A (ko) 2015-08-18
US20180051081A1 (en) 2018-02-22
NZ708445A (en) 2020-10-30
PH12015501318A1 (en) 2015-08-24
WO2014093678A2 (en) 2014-06-19
WO2015191861A1 (en) 2015-12-17
RU2015122228A (ru) 2017-01-19
CN105102479A (zh) 2015-11-25
SG11201504469XA (en) 2015-07-30
CN105102479B (zh) 2019-06-28
US20180057592A1 (en) 2018-03-01
US20140363442A1 (en) 2014-12-11
JP2016501892A (ja) 2016-01-21
EP2931751B1 (en) 2020-02-05
EP2931751A4 (en) 2016-07-13
BR112015013431A2 (pt) 2017-11-14
WO2014093678A3 (en) 2014-11-27
IL239339A0 (en) 2015-07-30
AU2013359167A1 (en) 2015-06-11
EP2931751A2 (en) 2015-10-21
ES2786083T3 (es) 2020-10-08
US10676524B2 (en) 2020-06-09
US10669336B2 (en) 2020-06-02
US20150274826A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
PH12015501318A1 (en) Therapeutic cd47 antibodies
EA201170716A1 (ru) Антитела к с-мет
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
WO2014190356A3 (en) Anti-b7-h5 antibodies and their uses
EA201590247A1 (ru) Антитела к siglec-15
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
MX361712B (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dell4) y usos de los mismos.
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
HK1201279A1 (en) Antibody and methods for selective inhibition of t-cell responses
MY166776A (en) Humanised anti-ctla4 antibodies
WO2009048537A3 (en) Humanized antibody
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
EP2586795A3 (en) Use of anti-amyloid beta antibody in ocular diseases
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
WO2014012007A3 (en) Rspo3 binding agents and uses thereof